Anticancer and DNA Binding Activities of Platinum (IV) Complexes; Importance of Leaving Group Departure Rate
- 12 January 2014
- journal article
- research article
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 172 (5) , 2604-2617
Abstract
The two six-coordinate Pt(IV) complexes, containing bidentate nitrogen donor/methyl ligands with general formula [Pt(X)2Me2(tbu2bpy)], where tbu2bpy = 4,4′-ditert-butyl-2,2′-bipyridine and X = Cl (C1) or Br (C2), serving as the leaving groups were synthesized for evaluation of their anticancer activities and DNA binding properties. To examine anticancer activities of the synthetic complexes, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and ethidium bromide/acridine orange (EB/AO) staining method were performed. The binding properties of these complexes to DNA and purine nucleotides were examined, using different spectroscopic techniques. These complexes demonstrated significant anticancer activities against three cancer cell lines Jurkat, K562, and MCF-7. On the basis of the results of EB/AO staining, C1 and C2 were also capable to induce apoptosis in cancer cells. These complexes comprise halide leaving groups, displaying different departure rates; accordingly, they demonstrated slightly dissimilar anticancer activity and significantly different DNA/purine nucleotide binding properties. The results of DNA interaction studies of these complexes suggest a mixed-binding mode, comprising partial intercalation and groove binding. Overall, the results presented herein indicate that the newly synthesized Pt(IV) complexes are promising class of the potential anticancer agents which can be considered as molecular templates in designing novel platinum anticancer drugs. This study also highlights the importance of leaving group in anticancer activity and DNA binding properties of Pt(IV) complexes.Keywords
This publication has 26 references indexed in Scilit:
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- Synthesis, Characterization, and Cytotoxicity of Platinum(IV) Carbamate ComplexesInorganic Chemistry, 2011
- Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor TissueAnti-Cancer Agents in Medicinal Chemistry, 2007
- Intrinsic Cisplatin Resistance in Lung and Ovarian Cancer Cells Propagating in Medium Acutely Depleted of FolateNutrition and Cancer, 2006
- Platinum Complexes as Anticancer AgentsRecent Patents on Anti-Cancer Drug Discovery, 2006
- Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug ResistanceChemical Reviews, 2003
- Mechanisms of resistance to cisplatinMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Methyl(hydrido)platinum(IV) Complexes: X-ray Structure of the First (μ-Hydrido)diplatinum(IV) ComplexOrganometallics, 1997
- Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexesBritish Journal of Cancer, 1992
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977